181 related articles for article (PubMed ID: 8418688)
21. [Usefulness of scintigraphy images with 111In-CYT-103 in the diagnosis of colonic and rectal recurrence].
García-Fernández R; Luna-Pérez P; Hernández-Hernández DM; Iwasaki-Otake L; Pichardo-Romero P; Rodríguez-Ramirez S
Gac Med Mex; 2002; 138(2):139-44. PubMed ID: 12001423
[TBL] [Abstract][Full Text] [Related]
22. The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report.
Method MW; Serafini AN; Averette HE; Rodriguez M; Penalver MA; Sevin BU
Cancer; 1996 Jun; 77(11):2286-93. PubMed ID: 8635097
[TBL] [Abstract][Full Text] [Related]
23. Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma.
Markowitz A; Saleemi K; Freeman LM
Clin Nucl Med; 1993 Aug; 18(8):685-700. PubMed ID: 8403703
[TBL] [Abstract][Full Text] [Related]
24. Detection of recurrent colorectal carcinoma with In-111 CYT-103 scintigraphy in a patient with nondiagnostic MRI and CT.
Edlin JP; Kahn D
Clin Nucl Med; 1994 Nov; 19(11):1004-7. PubMed ID: 7842571
[TBL] [Abstract][Full Text] [Related]
25. A practical approach to planar and SPECT imaging of 111In-CYT-103.
Collier BD; Trembath LA; Liu Y; Turoglu HT; Patel N; Thakur S
Targeted Diagn Ther; 1992; 6():191-210. PubMed ID: 1576346
[No Abstract] [Full Text] [Related]
26. Multicenter clinical trial of 111In-CYT-103 in patients with ovarian cancer.
Gallup DG
Targeted Diagn Ther; 1992; 6():111-24. PubMed ID: 1576342
[No Abstract] [Full Text] [Related]
27. Immunoscintigraphy with a new indium-111-labeled monoclonal antibody (MAb 1A3) in patients with colorectal cancer.
Philpott GW; Siegel BA; Schwarz SW; Connett JM; Rocque PA; Fleshman JW; Wallis JW; Baumann M; Sun Y; Martell AE
Dis Colon Rectum; 1994 Aug; 37(8):782-92. PubMed ID: 8055723
[TBL] [Abstract][Full Text] [Related]
28. In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: safety, sensitivity, and preliminary clinical results.
Abdel-Nabi H; Doerr RJ; Chan HW; Balu D; Schmelter RF; Maguire RT
Radiology; 1990 Apr; 175(1):163-71. PubMed ID: 2315476
[TBL] [Abstract][Full Text] [Related]
29. Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels.
Patt YZ; Podoloff DA; Curley S; Kasi L; Smith R; Bhadkamkar V; Charnsangavej C
J Clin Oncol; 1994 Mar; 12(3):489-95. PubMed ID: 8120546
[TBL] [Abstract][Full Text] [Related]
30. Detection of primary colorectal cancer with indium 111 monoclonal antibody B72.3.
Doerr RJ; Abdel-Nabi H; Baker JM; Steinberg S
Arch Surg; 1990 Dec; 125(12):1601-5. PubMed ID: 2244814
[TBL] [Abstract][Full Text] [Related]
31. OncoScint CR103 imaging in the surgical management of patients with colorectal cancer.
Doerr RJ; Abdel-Nabi HH
Targeted Diagn Ther; 1992; 6():89-109. PubMed ID: 1576352
[No Abstract] [Full Text] [Related]
32. Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature.
Pinkas L; Robins PD; Forstrom LA; Mahoney DW; Mullan BP
Nucl Med Commun; 1999 Aug; 20(8):689-96. PubMed ID: 10451876
[TBL] [Abstract][Full Text] [Related]
33. Oncoscint for detection of disseminated colorectal and ovarian cancer.
Med Lett Drugs Ther; 1993 Jun; 35(898):52-3. PubMed ID: 8497207
[No Abstract] [Full Text] [Related]
34. Detection of colorectal carcinoma by anti-CEA monoclonal antibody (IOR-CEA1) labeled with 99mTc scintigraphy.
Sirisriro R; Boonkitticharoen V; Kraiphibul P; Ratanatharathorn V; Sumboonnanon K; Kanjanapitak A; Kuhapremma T; Sritara C; Puchinda D; Chouplywech P; Jalayondeja V; Pekanan P; Rochanawutanon M; Intaramarn C; Ayudhya AN; Chokesuwathana P
Hepatogastroenterology; 2000; 47(32):405-13. PubMed ID: 10791201
[TBL] [Abstract][Full Text] [Related]
35. Superiority of SPET to planar imaging in the detection of colorectal carcinomas with 111In monoclonal antibodies.
Nabi HA; Erb DA; Cronin VR
Nucl Med Commun; 1995 Aug; 16(8):631-9. PubMed ID: 7491174
[TBL] [Abstract][Full Text] [Related]
36. Differences in biodistribution of indium-111-and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer.
Yokoyama K; Carrasquillo JA; Chang AE; Colcher D; Roselli M; Sugarbaker P; Sindelar W; Reynolds JC; Perentesis P; Gansow OA
J Nucl Med; 1989 Mar; 30(3):320-7. PubMed ID: 2738661
[TBL] [Abstract][Full Text] [Related]
37. Impact of 111In-CYT-103 on the surgical management of patients with ovarian cancer.
Surwit EA
Targeted Diagn Ther; 1992; 6():125-40. PubMed ID: 1576343
[No Abstract] [Full Text] [Related]
38. Indium-labeled anti-colorectal carcinoma monoclonal antibody accumulation in non-tumored tissue in patients with colorectal carcinoma.
Abdel-Nabi HH; Chan HW; Doerr RJ
J Nucl Med; 1990 Dec; 31(12):1975-9. PubMed ID: 2266396
[TBL] [Abstract][Full Text] [Related]
39. Radioimmunoscintigraphy of recurrent colorectal carcinoma using 111In-labelled murine monoclonal antibody B72.3: a comparison with contrast-enhanced computed tomography.
Kmiot WA; Stonelake P; Sagar G; Donovan IA; Neoptolemos JP; Notghi A; Harding LK
Nucl Med Commun; 1993 Sep; 14(9):788-91. PubMed ID: 8233244
[TBL] [Abstract][Full Text] [Related]
40. Improved detection of hepatic lesions using MoAb B72.3 and a modified 111In labelling technique in patients with recurrent colon cancer.
Vijayakumar V; Blend MJ; Johnson DK; Seevers RH; Schnobrich KE; Bekerman C
Nucl Med Commun; 1993 Aug; 14(8):658-66. PubMed ID: 8371891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
